Sandra Horning, MD
The FDA has granted bevacizumab (Avastin) a full approval for the treatment of adult patients with glioblastoma that progressed following prior therapy, according to Genentech, the manufacturer of the VEGF inhibitor.1
In safety data from the AVF3708g study, the most common all-grade adverse events in the single-agent bevacizumab arm were infection, fatigue, headache, hypertension, epistaxis, and diarrhea. Adverse events led to discontinuation in 4.8% of patients receiving bevacizumab. There were 2 patient deaths (retroperitoneal hemorrhage and neutropenic infection) that investigators considered as potentially related to bevacizumab treatment.
... to read the full story